blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2505189

EP2505189 - Stabilizing alkylglycoside compositions and method thereof [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.06.2019
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  06.07.2018
FormerGrant of patent is intended
Status updated on  14.03.2018
FormerExamination is in progress
Status updated on  02.02.2018
FormerGrant of patent is intended
Status updated on  01.10.2017
FormerExamination is in progress
Status updated on  09.01.2017
Most recent event   Tooltip09.07.2021Lapse of the patent in a contracting state
New state(s): HU		published on 11.08.2021  [2021/32]
Applicant(s)For all designated states
Aegis Therapeutics, LLC
16870 W. Bernardo Drive, Suite 390
San Diego CA 92127 / US
[2018/32]
Former [2012/40]For all designated states
Aegis Therapeutics, LLC
16870 W. Bernardo Drive, Suite 390
San Diego CA 92127 / US
Inventor(s)01 / Maggio, Edward T.
18775 Bernardo Trails Drive
San Diego, California 92128 / US
 [2012/40]
Representative(s)Lee, Nicholas John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2018/32]
Former [2012/40]Crooks, Elizabeth Caroline, et al
Kilburn & Strode LLP 20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date12165052.723.06.2006
[2012/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2505189
Date:03.10.2012
Language:EN
[2012/40]
Type: B1 Patent specification 
No.:EP2505189
Date:08.08.2018
Language:EN
[2018/32]
Search report(s)(Supplementary) European search report - dispatched on:EP03.09.2012
ClassificationIPC:A61K9/19, A61K47/26, A61K38/17, A61K38/28, A61K39/21, A61K38/08, A61K38/21, A61K38/27, A61K38/29, C12N7/00, A61K38/18
[2017/37]
CPC:
A61K47/26 (EP); A61K38/095 (EP,US); A61K38/1816 (EP);
A61K38/21 (EP); A61K38/27 (EP); A61K38/28 (EP);
A61K38/29 (EP); A61K9/0019 (EP); A61K9/0043 (EP);
A61K9/19 (EP); C12N7/00 (EP); C12N2740/16051 (EP) (-)
Former IPC [2012/40]A61K9/00, A61K9/19, A61K47/26, A61K38/17, A61K38/28, A61K39/21
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/32]
Former [2012/40]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren[2012/40]
English:Stabilizing alkylglycoside compositions and method thereof[2012/40]
French:Stabilisation de compositions alkylglycosidiques et procédé correspondant[2012/40]
Examination procedure18.01.2013Amendment by applicant (claims and/or description)
18.01.2013Examination requested  [2013/09]
17.05.2013Despatch of a communication from the examining division (Time limit: M06)
18.10.2013Reply to a communication from the examining division
27.05.2015Despatch of a communication from the examining division (Time limit: M06)
07.12.2015Reply to a communication from the examining division
21.03.2016Despatch of a communication from the examining division (Time limit: M06)
28.10.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
06.01.2017Reply to a communication from the examining division
02.10.2017Communication of intention to grant the patent
01.02.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.03.2018Communication of intention to grant the patent
02.07.2018Fee for grant paid
02.07.2018Fee for publishing/printing paid
02.07.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06785482.8  / EP2076281
EP09162179.7  / EP2158898
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060785482) is  13.04.2010
Opposition(s)09.05.2019No opposition filed within time limit [2019/29]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
06.01.2017Request for further processing filed
06.01.2017Full payment received (date of receipt of payment)
Request granted
26.01.2017Decision despatched
Fees paidRenewal fee
25.07.2012Renewal fee patent year 03
25.07.2012Renewal fee patent year 04
25.07.2012Renewal fee patent year 05
25.07.2012Renewal fee patent year 06
25.07.2012Renewal fee patent year 07
27.06.2013Renewal fee patent year 08
30.06.2014Renewal fee patent year 09
29.06.2015Renewal fee patent year 10
27.06.2016Renewal fee patent year 11
27.06.2017Renewal fee patent year 12
27.06.2018Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.06.2006
AT08.08.2018
CY08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
TR08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
[2021/32]
Former [2021/26]AT08.08.2018
CY08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
TR08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
Former [2020/29]AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
TR08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
PT08.12.2018
Former [2020/16]AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
TR08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2020/08]AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
MC08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/37]AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SI08.08.2018
SK08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/26]AT08.08.2018
CZ08.08.2018
DK08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SK08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/23]AT08.08.2018
CZ08.08.2018
EE08.08.2018
ES08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
SK08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/22]AT08.08.2018
CZ08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
RO08.08.2018
SE08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/21]AT08.08.2018
FI08.08.2018
IT08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
SE08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/13]AT08.08.2018
FI08.08.2018
LT08.08.2018
LV08.08.2018
NL08.08.2018
PL08.08.2018
SE08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/10]AT08.08.2018
FI08.08.2018
LT08.08.2018
NL08.08.2018
PL08.08.2018
SE08.08.2018
BG08.11.2018
GR09.11.2018
IS08.12.2018
Former [2019/09]FI08.08.2018
LT08.08.2018
NL08.08.2018
IS08.12.2018
Former [2019/08]FI08.08.2018
LT08.08.2018
IS08.12.2018
Former [2019/07]LT08.08.2018
Documents cited:Search[XI]WO2006025882  (UAB RESEARCH FOUNDATION [US], et al) [X] 1,2,4-9,11,13,15 * claims 1,2,8,17,47,90,94,123,131 * * paragraphs [0008] , [0016] , [0021] , [0033] , [0034] , [0037] , [0070] , [0079] , [0104] , [0072] , [0058] , [0119] * * example 1 *[I] 12,14
Examination   - Hiroshi Tachibana ET AL, "Differentiation of Entamoeba histolytica from E. dispar facilitated by monoclonal antibodies against a 150-kDa surface antigen", Parasitol Res, doi:10.1111/j.1423-0410.2006.00879.x, (19970501), pages 435 - 439, URL: https://rd.springer.com/article/10.1007/s004360050276, (20160310), XP055257334

DOI:   http://dx.doi.org/10.1007/s004360050276
by applicantUS3219656
 US3839318
 AT382381B
 AT386414B
 WO9117271
 WO9119481
 WO9201047
 US5661130
    - "Posttranslational Modifications: Perspectives and Prospects", WOLD, F., POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, ACADEMIC PRESS, (1983), page 1 12
    - SEIFTER ET AL., METH. ENZYMOL., (1990), vol. 182, page 626 646
    - RATTAN ET AL., "Protein Synthesis: Posttranslational Modifications and Aging", AM. N.Y. ACAD. SCI., (1992), vol. 663, page 48 62
    - HUSE ET AL., SCIENCE, (1989), vol. 246, page 1275 1281
    - WARD ET AL., NATURE, (1989), vol. 341, page 544 546
    - BRAIN RESEARCH, (1999), vol. 838, pages 27 - 36
    - ROSEVEAR ET AL., BIOCHEMISTRY, (1980), vol. 19, pages 4108 - 4115
    - KOELTZOW; URFER, J. AM. OIL CHEM. SOC., (1984), vol. 61, pages 1651 - 1655
    - LI ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 10723 - 10726
    - GOPALAN ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 9629 - 9638
    - CHEMICAL ABSTRACTS, Database accession no. 110:137536P
    - GRUBER, H.; GREBER, G., "Reactive Sucrose Derivatives", CARBOHYDRATES AS ORGANIC RAW MATERIALS, pages 95 - 116
    - "Hydrogen Fluoride, Solvent and Reagent for Carbohydrate Conversion Technology", DEFAYE, J.; PEDERSON, C., Carbohydrates as Organic Raw Materials, VCH PUBLISHERS, (1991), pages 247 - 265
    - FERENCI, T., J. BACTERIOL, (1980), vol. 144, pages 7 - 11
    - TSUCHIYA, T., CHEM. PHARM. BULL., (1985), vol. 33, pages 503 - 508
    - BINDER, T. P.; ROBYT, J. F., CARBOHYDR. RES., (1985), vol. 140, pages 9 - 20
    - CHEMICAL ABSTRACTS, Database accession no. 108:114719
    - GRUBER; GREBER, NN, pages 95 - 116
    - GRUBER; GREBER, CHEM. ABSTR., pages 95 - 116
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO
    - TJERNBERG ET AL., J. BIOL. CHEM., (1999), vol. 274, pages 12619 - 12625
    - AINGE G; BOWLES, J.A.; MCCORMICK, S.G. ET AL., "Lack of deleterious effects of corticosteroid sprays containing benzalkonium chloride on nasal ciliated epithelium", DRUG INVEST, (1994), vol. 8, pages 127 - 33
    - ANDYA J; MAA, YF ET AL., "The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody", PHARM RES, (1999), vol. 16, no. 3, doi:doi:10.1023/A:1018805232453, pages 350 - 8, XP008003520

DOI:   http://dx.doi.org/10.1023/A:1018805232453
    - ARAKAWA, T.; TIMASHEFF, S.N., "Stabilization of protein structure by sugars", BIOCHEMISTRY, (1982), vol. 21, page 6536 6544
    - ARAKAWA, T.; TIMASHEFF, S.N., "Stabilization of proteins by osmolytes", BIOPHYS. J., (1985), vol. 47, page 411414
    - BERG OH; HENRIKSEN, R.N.; STEINSVAG, S.K., "The effect of a benzalkonium chloride-containing nasal spray on human respiratory mucosa in vitro as a function of concentration and time of action", PHARMACOL TOXICOL, (1995), vol. 76, pages 245 - 9
    - BRAAT JP; AINGE, G.; BOWLES, J.A. ET AL., "The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: A combined functional, light, scanning and transmission electron microscopy study", CLIN EXP ALLERGY, (1995), vol. 25, pages 957 - 65
    - BRENNEMAN, D.E.; J.M. BUZY; M.R. RUFF; C.B. PERT., "Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus", DRUG DEVEL RES., (1988), vol. 15, doi:doi:10.1002/ddr.430150403, pages 361 - 369, XP055039001

DOI:   http://dx.doi.org/10.1002/ddr.430150403
    - TP, HESELTINE PN; PARKER ES; EATON E; INGRAHAM LJ; GILL M; RUFF M; PERT CB; GOODWIN FK., "Improvement in AIDS patients on peptide T", LANCET, (1989), vol. 2, no. 8656, pages 226 - 7
    - CASADEVALL N ET AL., "Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin", N ENGL J MED, (2002), vol. 346, no. 7, doi:doi:10.1056/NEJMoa011931, pages 469 - 75, XP009073085

DOI:   http://dx.doi.org/10.1056/NEJMoa011931
    - CHAWLA, A.S.; HINBERG, I.; BLAIS, P.; JOHNSON, D., "Aggregation of insulin, containing surfactants, in contact with different materials", DIABETES, (1985), vol. 34, doi:doi:10.2337/diabetes.34.5.420, pages 420 - 24, XP002919172

DOI:   http://dx.doi.org/10.2337/diabetes.34.5.420
    - CLODFELTER, "Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide", PHARM RES, (1998), vol. 15, doi:doi:10.1023/A:1011918719017, pages 254 - 62, XP000945303

DOI:   http://dx.doi.org/10.1023/A:1011918719017
    - CLODFELTER DK; PEKAR AH; REBHUN DM; DESTRAMPE KA; HAVEL HA; MYERS SR; BRADER ML., "Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide", PHARM RES, (1998), vol. 15, no. 2, doi:doi:10.1023/A:1011918719017, pages 254 - 62, XP000945303

DOI:   http://dx.doi.org/10.1023/A:1011918719017
    - DEPALMA A, "Improving Stability While Adding Value", GENETIC ENG. NEWS, (20060115), vol. 26, no. 2
    - GRAF P; ENERDAL, J.; HALLEN, H., "Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis", ARCH OTOLARYNGOL HEAD NECK SURG, (1999), vol. 125, pages 1128 - 32
    - HESELTINE, P.N.; K. GOODKIN; J.H. ATKINSON; B. VITIELLO; J. ROCHON; R.K. HEATON; E.M. EATON; F.L. WILKIE; E. SOBEL; S.J. BROWN, "Randomized double-blind placebo-controlled trial of peptide T for HIV- associated cognitive impairment", ARCH NEUROL., (1998), vol. 55, pages 41 - 51
    - HOLM AF; FOKKENS, W.J.; GODTHELP, T. ET AL., "A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: A safety and biopsy study", CLIN OTOLATYNGOL, (1998), vol. 23, pages 69 - 73
    - KING HD; DUBOWCHIK GM; MASTALERZ H; WILLNER D; HOFSTEAD SJ; FIRESTONE RA; LASCH SJ; TRAIT PA, "Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains", J MED CHEM, (2002), vol. 45, no. 19, doi:doi:10.1021/jm020149g, pages 4336 - 43, XP001193748

DOI:   http://dx.doi.org/10.1021/jm020149g
    - KLOSSEK JM; LALIBERTE, F.; LALIBERTE, M.F. ET AL., "Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long term treatment of perennial allergic rhinitis", RHINOLOGY, (2001), vol. 39, pages 17 - 22
    - KOSTEN TR; ROSEN MI; MCMAHON TL; BRIDGE TP; O'MALLEY SS; PEARSALL R; O'CONNOR PG., "Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T", AM J DRUG ALCOHOL ABUSE, (1997), vol. 23, no. 4, pages 543 - 53
    - LANGE B; LUKAT, K.F.; BACHERT, C., "Local tolerability of a benzalkonium chloride-containing homeopathic nasal spray", ALLERGOLOGIE, (2004), vol. 27, no. 3, page 102
    - MARPLE B; ROLAND, P.; BENNINGER, M., "Safety review of benzalkonium chloride used as a preservative in i-ntranasal solutions: An overview of conflicting data and opinions", OTOLARYNGOLOGY- HEAD AND NECK SURGERY, (2004), vol. 130, no. 1, pages 131 - 141
    - MCMAHON C; DARBY, Y.; RYAN, R. ET AL., "Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo", CLIN OTOLARYNGOL, (1997), vol. 22, pages 318 - 22
    - PERT CB; RUFF MR, "Peptide T[4-8]: a sequence in the AIDS virus envelope which blocks infectivity is essentially conserved across nine isolates", CLIN NEUROPHARMACOL, (1986), vol. 9, no. 4, pages 482 - 4
    - PERT CB; RUFF MR; HILL JM., "AIDS as a neuropeptide disorder: peptide T, VIP, and the HIV receptor", PSYCHOPHARMACOL BULL, (1988), vol. 24, no. 3, pages 315 - 9
    - PERT ET AL., "Chemokines receptor 5 antagonist D-ala Peptide T amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease", NEUROSCIENCE, (2005), vol. 134, pages 671 - 676
    - PEZRON I; MITRA R; PAL D; MITRA AK, "Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3", J PHARM SCI, (2002), vol. 91, no. 4, doi:doi:10.1002/jps.10114, pages 1135 - 46, XP002528202

DOI:   http://dx.doi.org/10.1002/jps.10114
    - MARIA T. POLIANOVA; GIFFORD LEOUNG; SCOTT STRANG; CANDACE B. PERT; FRANCIS W. RUSCETTI; MICHAEL R. RUFF, "Anti-viral and immunological benefits in HIV patients receiving peptide", T PEPTIDES, (2003), vol. 24, no. 7, pages 1093 - 8
    - PORTER WR; STAACK H; BRANDT K; MANNING MC, "Thermal stability of low molecular weight uroldnase during heat treatment. I. Effects of protein concentration, pH and ionic strength", THROMB RES, (1993), vol. 71, no. 4, doi:doi:10.1016/0049-3848(93)90196-U, pages 265 - 79, XP026465030

DOI:   http://dx.doi.org/10.1016/0049-3848(93)90196-U
    - PUROHIT VS; MIDDAUGH CR; BALASUBRAMANIAN SV, "Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice", J PHARM SCI, (2006), vol. 95, no. 2, pages 358 - 71
    - RIECHELMANN H; DEUTSCHLE, T.; STUHLMILLER, A.; GRONAU, S.; BURNER, H., "Nasal toxicity of benzalkonium chloride", AMERICAN JOURNAL OF RHINOLOGY, (2004), vol. 18, no. 5, pages 291 - 299
    - ROCCATANO ET AL., "Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure ion-nation in peptides: A molecular dynamics study", PNAS, (2002), vol. 99, no. 19, pages 12179 - 12184
    - RAYCHAUDHURIA ET AL., "Immunomodulatory effects of Peptide T on Th 1/Th 2", CYTOKINES INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1999), vol. 21, pages 609 - 615
    - REDWINE, LS; RONE, JD; PERT, CB; NIXON, R.; VANCE, M.; SANDLER, B.; LUMPKIN, MD; RUFF, MR., "GP120(V2)-Derived Peptide T Blocks GP120/CCR5 Chemokine Receptor Mediated Chemotaxis", CLINICAL IMMUNOLOGY., (1999), vol. 93, page 124
    - ROY S; JUNG R; KERWIN BA; RANDOLPH TW; CARPENTER JF, "Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations", J PHARM SCI, (2005), vol. 94, no. 2, pages 382 - 96
    - RUFF MR; HALLBERG PL; HILL JM; PERT CB, "Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attaclmient", LANCET, (1987), vol. 2, no. 8561, page 751
    - RUFF MR; MELENDEZ-GUERRERO LM; YANG QE; HO WZ; MIKOVITS JW; PERT CB; RUSCETTI FA, "Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5", ANTIVIRAL RES, (2001), vol. 52, no. 1, pages 63 - 75
    - RUFF MR; POLIANOVA M; YANG QB; LEOUNG GS; RUSCETTI FW; PERT CB, "Update On D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors", CURR HIV RES, (2003), vol. 1, no. 1, doi:doi:10.2174/1570162033352066, pages 51 - 67, XP002568509

DOI:   http://dx.doi.org/10.2174/1570162033352066
    - RUFF MI; SMITH C; KINGAN T; JAFFE H; HESELTINE P; GILL MA; MAYER K; PERT CB; BRIDGE TP, "Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS", PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (1991), vol. 15, no. 6, doi:doi:10.1016/0278-5846(91)90008-O, pages 791 - 801, XP025531827

DOI:   http://dx.doi.org/10.1016/0278-5846(91)90008-O
    - SATO, S.; EBERT, C.D.; KIM, S.W., "Prevention of insulin self-association and surface adsorption", J. PHARM. SCI., (1983), vol. 72, pages 228 - 232
    - SIMPSON, D.M.; D. DORFMAN; R.K. OLNEY; G. MCKINLEY; J. DOBKIN; Y. SO; J. BERGER; M.B. FERDON; B. FRIEDMAN, "Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group", NEUROLOGY, (1996), vol. 47, pages 1254 - 1259
    - SLUZKY V; TAMADA JA; KLIBANOV AM; LANGER R., "Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces", PROC NATL ACAD SCI U S A, (1991), vol. 88, no. 21, doi:doi:10.1073/pnas.88.21.9377, pages 9377 - 81, XP055262764

DOI:   http://dx.doi.org/10.1073/pnas.88.21.9377
    - SONNICHSEN FD; VAN EYK JE; HODGES RS; SYKES BD, "Effect of trifluoroethanol on protein secondary structure: an NMR and CD using a synthetic actin peptide", BIOCHEMISTRY, (1992), vol. 31, no. 37, pages 8790 - 8798
    - THUROW, H.; GEISEN, K., "Stabilization of dissolved proteins against denaturation at hydrophobic surfaces", DIABETOL, (1984), vol. 27, pages 212 - 218, XP001096189
    - WRIGHT J ET AL., "Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation", MOL THER, (2005), vol. 12, no. 1, doi:doi:10.1016/j.ymthe.2005.02.021, pages 171 - 8, XP004974961

DOI:   http://dx.doi.org/10.1016/j.ymthe.2005.02.021
    - ZHANG MZ; WEN J; ARAKAWA T; PRESTRELSKI SJ., "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor", PHARM RES, (1995), vol. 12, no. 10, doi:doi:10.1023/A:1016219000963, pages 1447 - 52, XP009007833

DOI:   http://dx.doi.org/10.1023/A:1016219000963
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.